About Cooper Companies
Cooper Companies (COO) is a global medical device company worth $7.33 billion. The company has two business units, CooperVision and CooperSurgical. CooperVision provides high quality contact lens products and focused practitioner support. CooperSurgical focuses on supplying women’s health clinicians with market-leading products and treatment options to improve the delivery of healthcare to women.
The stock movement of Cooper Companies (COO) on a weekly, monthly, and year-to-date basis is -8.42%, -13.84%, and -6.89%, respectively. The PowerShares DWA Healthcare Momentum Portfolio ETF (PTH) holds Cooper Companies (COO). The ETF’s year-to-date price movement is 9.36%. Some of Cooper’s competitors are Hologic (HOLX), Boston Scientific Corporation (BSX), Johnson & Johnson (JNJ), and TearLab (TEAR).
Cooper Companies’ performance in 2Q15
2Q15 earnings were a mixed bag for Cooper Companies with revenue up for CooperVision and down for CooperSurgical. To improve the performance and increase synergy, CooperSurgical has acquired Reprogenetics, the largest genetics laboratory specializing in preimplantation genetic screening and preimplantation genetic diagnosis used during the in-vitro fertilization process. The deal is valued at $46.5 million and is expected to be neutral for fiscal 2015 and 2016 EPS (earnings per share).
Performance of Cooper Companies in 3Q15
Cooper Companies (COO) reported revenue of $461.7 million as compared to $434.7 million in 2Q15, an increase of 6.2% on a quarterly basis. The revenue of CooperVision has gone up by 7.2% to $385.5 million. CooperSurgical has gone up by 1.4% to $76.2 million as compared to 2Q15.